Your browser doesn't support javascript.
loading
Exploring the Biosynthetic Potential of Tistrella Species for Producing Didemnin Antitumor Agents.
Zhang, Haili; Huang, Shipeng; Zou, Xiaolin; Shi, Wenguang; Liang, Mengdi; Lin, Yang; Zheng, Min; Tang, Xiaoyu.
Affiliation
  • Zhang H; Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • Huang S; College of Pharmacy, Guangxi Medical University, Nanning 530021, China.
  • Zou X; Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • Shi W; Department of Chemistry and Shenzhen Grubbs Institute, Southern University of Science and Technology, Shenzhen 518000, China.
  • Liang M; Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • Lin Y; Department of Chemistry and The Swire Institute of Marine Science, The University of Hong Kong, Pokfulam Road, Hong Kong, China.
  • Zheng M; Institute of Chemical Biology, Shenzhen Bay Laboratory, Shenzhen 518132, China.
  • Tang X; Institute of Infectious Diseases, Shenzhen Bay Laboratory, Shenzhen 518132, China.
ACS Chem Biol ; 2024 Sep 23.
Article in En | MEDLINE | ID: mdl-39312286
ABSTRACT
Didemnins are a class of cyclic depsipeptides derived from sea tunicates that exhibit potent anticancer, antiviral, and immunosuppressive properties. Although certain Tistrella species can produce didemnins, their complete biosynthetic potential remains largely unexplored. In this study, we utilize feature-based molecular networking to analyze the metabolomics of Tistrella mobilis and Tistrella bauzanensis, focusing on the production of didemnin natural products. In addition to didemnin B, we identify nordidemnin B and [hysp2]didemnin B, as well as several minor didemnin analogs. Heterologous expression of the didemnin biosynthetic gene cluster in a Streptomyces host results in the production of only didemnin B and nordidemnin B in limited quantities. Isotope-labeling studies reveal that the substrate promiscuity of the adenylation domains during biosynthesis leads to the accumulation of nordidemnin B and [hysp2]didemnin B. Additionally, precursor-directed biosynthesis is applied to generate eight novel didemnin derivatives by supplementing the culture with structurally related amino acids. Furthermore, we increased the titers of nordidemnin B and [hysp2]didemnin B by supplementing the fermentation medium with l-valine and l-isoleucine, respectively. Finally, both compounds undergo side-chain oxidation to enhance their biological activity, with their anticancer properties found to be as potent as plitidepsin.

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Chem Biol Year: 2024 Document type: Article Affiliation country: China Country of publication: United States

Full text: 1 Collection: 01-internacional Database: MEDLINE Language: En Journal: ACS Chem Biol Year: 2024 Document type: Article Affiliation country: China Country of publication: United States